Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
AssigneeBavarian Nordic A/S
InventorsRene Djurup, Sara Post Hansen
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for purification of Vaccinia viruses (W) and/or Vaccinia virus (W) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.
Claims22
An industrial-scale process for the purification of biologically active Vaccinia virus comprising:
- i) loading a solid-phase matrix, to which a ligand is attached, with a Vaccinia virus contained in a liquid-phase culture, wherein the ligand is glucosamine glycan (GAG) ligand;
- ii) washing the matrix;
- and
- iii) eluting the virus.
A method for the purification of biologically active Vaccinia virus comprising:
- i) loading a solid-phase matrix, to which a ligand is attached, with a Vaccinia virus contained in a liquid-phase culture, wherein the ligand is glucosamine glycan (GAG) ligand,
- wherein the solid-phase matrix comprises or is a membrane;
- ii) washing the matrix;
- and
- iii) eluting the virus.
A method for the purification of biologically active Vaccinia virus comprising:
- i) loading a solid-phase matrix, to which a ligand is attached, with a Vaccinia virus contained in a liquid-phase culture, wherein the ligand is glucosamine glycan (GAG) ligand,
- wherein the solid-phase matrix comprises a pore size of greater than 0.25 μm;
- ii) washing the matrix;
- and
- iii) eluting the virus.
Dependencies are inferred from the claim text.